CN1713909A - 氨基吲唑衍生物及其作为激酶抑制剂的用途 - Google Patents

氨基吲唑衍生物及其作为激酶抑制剂的用途 Download PDF

Info

Publication number
CN1713909A
CN1713909A CNA038256169A CN03825616A CN1713909A CN 1713909 A CN1713909 A CN 1713909A CN A038256169 A CNA038256169 A CN A038256169A CN 03825616 A CN03825616 A CN 03825616A CN 1713909 A CN1713909 A CN 1713909A
Authority
CN
China
Prior art keywords
phenyl
chloro
fluoro
indazole
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038256169A
Other languages
English (en)
Chinese (zh)
Inventor
D·莱叙斯
G·迪特吕克-罗塞
F·阿莱
D·巴班
T·鲁尼
G·蒂拉博斯奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CN1713909A publication Critical patent/CN1713909A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA038256169A 2002-12-12 2003-09-03 氨基吲唑衍生物及其作为激酶抑制剂的用途 Pending CN1713909A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FRFR0215720 2002-12-12
FR0215720A FR2848554A1 (fr) 2002-12-12 2002-12-12 Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
US60/444,630 2003-02-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010105043043A Division CN101979382A (zh) 2002-12-12 2003-09-03 氨基吲唑衍生物及其作为激酶抑制剂的用途

Publications (1)

Publication Number Publication Date
CN1713909A true CN1713909A (zh) 2005-12-28

Family

ID=32338720

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA038256169A Pending CN1713909A (zh) 2002-12-12 2003-09-03 氨基吲唑衍生物及其作为激酶抑制剂的用途
CN2010105043043A Pending CN101979382A (zh) 2002-12-12 2003-09-03 氨基吲唑衍生物及其作为激酶抑制剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010105043043A Pending CN101979382A (zh) 2002-12-12 2003-09-03 氨基吲唑衍生物及其作为激酶抑制剂的用途

Country Status (11)

Country Link
JP (1) JP4764168B2 (https=)
CN (2) CN1713909A (https=)
AR (1) AR041132A1 (https=)
AT (1) ATE520399T1 (https=)
FR (1) FR2848554A1 (https=)
ME (1) MEP25308A (https=)
MY (1) MY138085A (https=)
PE (2) PE20040996A1 (https=)
RS (1) RS20050421A (https=)
TW (1) TWI345561B (https=)
ZA (1) ZA200504681B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102388039A (zh) * 2009-02-26 2012-03-21 葛兰素集团有限公司 用作ccr4受体拮抗剂的吡唑衍生物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
CA2989519C (en) 2015-06-15 2023-09-26 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
CN115260165B (zh) * 2021-04-29 2024-08-06 中国科学院上海药物研究所 苯并含氮五元杂环化合物及其合成和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51143010A (en) * 1975-06-04 1976-12-09 Kao Corp Stable bleaching detergent composition
EP1317450B1 (en) * 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6593349B2 (en) * 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
WO2003028720A1 (en) * 2001-09-26 2003-04-10 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
BR0314098A (pt) * 2002-09-05 2005-07-19 Aventis Pharma Sa Derivados da aminoindazóis a tìtulo de medicamentos e composições farmacêuticas que os contêm

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102388039A (zh) * 2009-02-26 2012-03-21 葛兰素集团有限公司 用作ccr4受体拮抗剂的吡唑衍生物
CN102388039B (zh) * 2009-02-26 2015-07-15 葛兰素集团有限公司 用作ccr4受体拮抗剂的吡唑衍生物

Also Published As

Publication number Publication date
PE20040996A1 (es) 2005-01-28
TWI345561B (en) 2011-07-21
TW200422293A (en) 2004-11-01
JP2006516266A (ja) 2006-06-29
RS20050421A (sr) 2007-08-03
AR041132A1 (es) 2005-05-04
JP4764168B2 (ja) 2011-08-31
PE20091629A1 (es) 2009-11-16
ATE520399T1 (de) 2011-09-15
CN101979382A (zh) 2011-02-23
MY138085A (en) 2009-04-30
MEP25308A (en) 2010-06-10
ZA200504681B (en) 2006-08-30
FR2848554A1 (fr) 2004-06-18

Similar Documents

Publication Publication Date Title
CN1678589A (zh) 作为药物的新氨基吲唑衍生物与含有它们的药物组合物
CN1222511C (zh) 作为5－羟色胺－6配体的1－芳基－或1－烷基磺酰基－杂环基吲哚
CN100351236C (zh) 用作5－羟色胺－6配体的1－杂环基烷基－3－磺酰基－吲哚衍生物，其制备方法和用途
CN1229351C (zh) 杂环化合物和治疗心力衰竭及其它疾病的方法
CN1193025C (zh) 新的1,3－二氢－2h－吲哚－2－酮衍生物,它们的制备方法以及含有它们的药物组合物
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1039322C (zh) 吲哚衍生物的制备方法
CN1771244A (zh) 作为5－羟色胺－6配体的杂环－3－磺酰基吲唑
CN1150165C (zh) 用于治疗中枢神经系统紊乱的1-芳基磺酰基-2-芳基-吡咯烷衍生物
CN1582277A (zh) 用作糖原合酶激酶3β抑制剂的酰胺衍生物
CN1346348A (zh) 酰胺化合物及其药物用途
CN1473040A (zh) Cb1受体拮抗剂与西布茶明的组合形式、其药物组合物及其在治疗肥胖病中的应用
CN1933834A (zh) 吲唑甲酰胺衍生物在制备用于治疗和预防疟疾的药物中的用途
CN1468217A (zh) 脂肪族含氮五员环化合物
CN1035113A (zh) 用于治疗的杂环化合物
CN1582285A (zh) 用作糖原合酶激酶3β抑制剂(GSK3抑制剂)的杂芳胺化合物
CN1678317A (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1500081A (zh) 乙内酰硫脲及其在治疗糖尿病方面的用途
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1620455A (zh) 作为5－羟色胺－6配体的氮杂吲哚基烷基胺衍生物
CN1018614B (zh) 制备含n-杂环基-4-哌啶胺类的抗组胺组合物的方法
CN1535148A (zh) 调节钠通道的咪唑衍生物
CN1198817C (zh) 作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺
CN1305462A (zh) 具有止喘、抗变态反应、抗炎、免疫调节和神经保护作用的新的1,5和3－o－取代1h－吲唑类化合物,其制备方法以及作为药物的应用
CN1178923C (zh) 1,4-二氮杂环庚烷-2,5-二酮衍生物及其作为nk-1受体拮抗剂的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081447

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20051228

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1081447

Country of ref document: HK